Lung alkaline phosphatase as a marker of fibrosis in chronic interstitial disorders

Alkaline phosphatase (ALP) in lung lavage fluids is a marker of tissue damage and type II cell proliferation. Type II pneumocytes are extensively involved in fibrosis. The aim of our study was to verify whether local ALP activity can be held as a marker of fibrosis in chronic interstitial lung disor...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 1997, Vol.155 (1), p.249-253
Main Authors: CAPELLI, A, LUSUARDI, M, CERUTTI, C. G, DONNER, C. F
Format: Article
Language:English
Subjects:
Adult
Albumins - analysis
Alkaline Phosphatase - analysis
Biological and medical sciences
Biomarkers - analysis
Bronchoalveolar Lavage Fluid - chemistry
Clinical Enzyme Tests
Female
Humans
Lung - enzymology
Lung Diseases, Interstitial
Male
Medical sciences
Middle Aged
Pneumology
Prognosis
Pulmonary Fibrosis - diagnosis
Pulmonary Fibrosis - metabolism
Respiratory system : syndromes and miscellaneous diseases
Sarcoidosis, Pulmonary - pathology
Silicosis - pathology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alkaline phosphatase (ALP) in lung lavage fluids is a marker of tissue damage and type II cell proliferation. Type II pneumocytes are extensively involved in fibrosis. The aim of our study was to verify whether local ALP activity can be held as a marker of fibrosis in chronic interstitial lung disorders. ALP was determined in the bronchoalveolar lavage of 140 subjects: 25 control subjects, and 33 patients with silicosis, 38 with idiopathic pulmonary fibrosis (IPF), and 18 with Stage I, 16 with Stage II, and 10 with Stage III/IV sarcoidosis. We observed a significant augmentation of ALP activity in patients with IPF, as well as in those with Stages II and III/IV sarcoidosis. Albumin was higher in those with Stages I and II sarcoidosis, but it was normal in the other groups. Therefore, a significant increase in ALP:albumin ratio characterized IPF (median, 10.3; range, 2.4 to 83.2) and Stage III/IV sarcoidosis, (8.9, 4.4 to 103.1) as compared with Stage I (2, 1.1 to 18) and Stage II (4.7, 0.7 to 26.6) sarcoidosis, silicosis (6.5, 0.5 to 42.7), and the nonsmoker (6.1, 2.9 to 12.9) and smoker (6.4, 2 to 15.2) control groups. We conclude that an increase of the ALP: albumin ratio in bronchoalveolar lavage fluids from patients with chronic interstitial disorders may reflect a fibrosing progression.
ISSN:1073-449X
1535-4970
DOI:10.1164/ajrccm.155.1.9001320